Mentor, Inamed Saline Breast Implants Deemed Approvable By FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Saline breast implants manufactured by Mentor Corp. and Inamed Corp. should remain on the U.S. market provided the device manufacturers beef up labeling and physician training to help insure that patients are fully informed of any possible adverse outcomes, FDA's General and Plastic Surgery Devices Advisory Panel recommended at a March 1 meeting in Gaithersburg, Maryland.
You may also be interested in...
FDA, Congress Examine Saline Implant Data; Silicone PMA Expected In 2002
Mentor and Inamed should reconvene focus groups to review patient labeling changes for saline-filled breast implants, FDA's General and Plastic Surgery Devices Panel recommended July 9 at its meeting in Gaithersburg, Maryland
FDA, Congress Examine Saline Implant Data; Silicone PMA Expected In 2002
Mentor and Inamed should reconvene focus groups to review patient labeling changes for saline-filled breast implants, FDA's General and Plastic Surgery Devices Panel recommended July 9 at its meeting in Gaithersburg, Maryland
CTD Clinical Follow-Up Still Needed For Breast Implants, FDA Maintains
Breast implant patients should be monitored for symptoms of connective tissue disease annually for a minimum of 10 years post-implantation, FDA advises in final guidance to be issued Aug. 13.